Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
Rhea-AI Summary
Zevra Therapeutics (Nasdaq: ZVRA) will ring the Nasdaq opening bell on Monday, February 9, 2026. CEO Neil F. McFarlane will deliver opening remarks at 9:24 a.m. ET followed by the bell at 9:30 a.m. ET. The ceremony is viewable via Nasdaq's live stream and on the Nasdaq MarketSite Tower in New York.
Positive
- None.
Negative
- None.
News Market Reaction – ZVRA
On the day this news was published, ZVRA gained 4.00%, reflecting a moderate positive market reaction. Argus tracked a peak move of +10.4% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $21M to the company's valuation, bringing the market cap to $533M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news scan flagged only ATYR moving in momentum (-4.06%, down). With ZVRA’s pre-news direction marked as down and no other peers in the same direction, activity appears stock-specific rather than a coordinated biotech sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 26 | Clinical data presentations | Positive | +0.6% | Multiple MIPLYFFA analyses presented at WORLDSymposium for NPC data visibility. |
| Jan 08 | Conference appearance | Positive | +1.8% | Management presentation and investor meetings at J.P. Morgan Healthcare Conference. |
| Dec 29 | Commercial agreement | Positive | -0.6% | Distribution agreement with Uniphar to broaden MIPLYFFA access outside Europe. |
| Dec 12 | Equity inducement grants | Neutral | -1.9% | Stock option grants to new employees under 2023 inducement award plan. |
| Dec 02 | Board changes | Neutral | -2.0% | Appointment of Alicia Secor to board and retirement of Wendy Dixon. |
Recent news has mostly been operational and event-focused, with modest price reactions that generally align with the directional tone of the announcements.
Over the past few months, Zevra has issued multiple operational updates. In Q3 2025, it reported sharply improved results with revenue of $26.1M versus $3.7M a year earlier and a much smaller quarterly loss. Subsequent news covered executive presentations at the J.P. Morgan 44th Annual Healthcare Conference, new MIPLYFFA® data at the 22nd Annual WORLDSymposium™, a distribution agreement to broaden access to MIPLYFFA, inducement equity grants, and a board refresh. The current Nasdaq opening-bell announcement fits into this stream of visibility and corporate-profile events rather than a fundamental change.
Market Pulse Summary
This announcement highlights Zevra’s participation in a Nasdaq opening-bell ceremony on February 9, 2026, which primarily serves to increase corporate visibility rather than change fundamentals. In recent quarters, the story has been driven more by improved financials, including Q3 2025 revenue of $26.1M and significantly reduced losses, as well as commercialization efforts for MIPLYFFA®. Investors may focus on future earnings reports, commercial execution, and additional clinical or regulatory updates as more material drivers.
AI-generated analysis. Not financial advice.
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has been invited to ring the Nasdaq opening bell on Monday, February 9, 2026. Neil F. McFarlane, Zevra's President and Chief Executive Officer, will deliver opening remarks at 9:24 a.m. followed by the bell ringing at 9:30 a.m. ET, signifying the start of the day's trading session.
The opening bell ceremony can be seen live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony and on the Nasdaq MarketSite Tower at 43rd and Broadway in New York, NY.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a purpose-driven, commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases. The company’s commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disorder, provides a strong corporate foundation and validates its ability to advance therapies. In addition, the company is broadening access through geographic expansion opportunities and has a pipeline of rare disease programs. Zevra is a patient-centric organization guided by our values of accountability, integrity, innovation and courage, with the goal of creating long-term value for patients, partners, and shareholders.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.
Investor Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
Media Contact
Julie Downs
+1 (508) 246-3230
jdowns@zevra.com
FAQ
When will Zevra Therapeutics (ZVRA) ring the Nasdaq opening bell on February 9, 2026?
How can investors watch Zevra Therapeutics (ZVRA) ringing the Nasdaq bell on February 9, 2026?
Who will represent Zevra Therapeutics (ZVRA) at the Nasdaq opening on February 9, 2026?
Does Zevra Therapeutics' (ZVRA) Nasdaq bell-ringing on February 9, 2026 imply any new financial disclosures?
What time should shareholders tune in to hear Zevra Therapeutics (ZVRA) remarks on February 9, 2026?
Where will the Zevra Therapeutics (ZVRA) Nasdaq opening bell ceremony take place on February 9, 2026?
